HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 05, May 2018 – Dental health - The root to good health       » Drugs to watch 2018       » Dragonfly-inspired nano coating kills bacteria upon contact       » New compound improves stroke recovery in monkeys and mice       » Cancer stem cell therapy breakthrough       » Draft genome of tea plant sequenced      
EYE ON CHINA
UroFlex now CE-marked; Chinese SFDA approval for Cellvizio
Mauna Kea Technology's UroFlex confocal miniprobe has received CE mark approval for use during cystoscopy procedures. UroFlex is believed to be the first optical biopsy probe designed for urological applications and allows the company to enter the EUR 1 billion European urology device market. The new probe allows physicians to obtain optical biopsies that may facilitate the diagnosis, surveillance and treatment of patients with bladder cancer. The CE mark extends Mauna Kea's Cellvizio portfolio beyond the gastrointestinal tract and lungs into the field of urology.

Clinical studies have demonstrated that optical biopsies with Cellvizio could help urologists determine if they have removed all cancerous cells during transurethral resection of the bladder tumour, the initial surgical procedure that a patient undergoes after the diagnosis of bladder cancer. Data also showed that optical biopsies can help physicians characterize lesions during long-term surveillance of bladder cancer patients.

In addition, Mauna Kea's Cellvizio has received SFDA approval in China, one of the fastest growing, largest medical device markets in the world. Concurrently, Mauna Kea has entered into a strategic partnership with Fujifilm Investment Co, a subsidiary of Fujifilm Holdings. The partners will work together to develop the Cellvizio market throughout China in various indications, such as gasteroenterology and pulmonology.

Fujifilm benefits from growth in its endoscopy market in China, and has established a strong distribution network all over the country. There are 800 advanced endoscopy centres in tertiary referral hospitals in China, which will constitute the primary target for Cellvizio.

Cellvizio is a probe-based confocal laser endomicroscopy system that provides high-resolution cellular views of tissue inside the body. Cellvizio has 510(k) clearance from the FDA and the European CE mark for use in the gastrointestinal tract, biliary and pancreatic ducts and lungs.

Click here for the complete issue.

NEWS CRUNCH  
news Shire, Microsoft and EURORDIS form Global Commission to accelerate time to diagnosis for children with rare diseases
news EmTech Asia explores future of life, humanity and economy
news Biology of Ageing II - Impactful Interventions
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  
Subscribe to APBN E-Newsletter
Find us under 'Others' option to receive APBN e-newsletters thrice a month!

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Oncology / Biotech landscape in APAC
July:
Water management / Vaccination
August:
Regenerative medicine / Biotech start ups
September:
Digital healthcare / 3D printing
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy